Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials - Wikidata - wikimedia - TriplyDB

Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials

Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials

http://www.wikidata.org/entity/Q28166614

about

Platelet function and ageing The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism Antiplatelet therapy in ischemic stroke Preventable stroke and stroke prevention Use of the platelet function analyser (PFA-100) to quantify the effect of low dose aspirin in patients with ischaemic heart disease Aspirin resistance and its implications in clinical practice Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study A directional switch of integrin signalling and a new anti-thrombotic strategy.Non ST-elevation acute coronary syndrome.Preventing recurrent cerebrovascular events in patients with stroke or transient ischemic attack: the current data.Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended event A novel role of Eruca sativa Mill. (rocket) extract: antiplatelet (NF-κB inhibition) and antithrombotic activities.Antithrombotic and antiplatelet activities of Soshiho-tang extract.Chlorogenic acid inhibits human platelet activation and thrombus formation.Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis Antidepressants, antiplatelets and bleeding: one more thing to worry about?NSAIDs and Colorectal Cancer Control: Promise and Challenges Cangrelor for treatment of coronary thrombosis.Diagnosis of takotsubo cardiomyopathy is increasing over time in patients presenting as ST-elevation myocardial infarction Acute coronary syndrome (unstable angina and non-ST elevation MI).Antiplatelet therapy in ENT surgery: a review.Diagnosis and treatment of platelet hyperactivity in relation to thrombosis in dogs and cats.Adverse drug events as a cause of hospitalization in older adults.Prognosis and Predictors of Rebleeding After Bronchial Artery Embolization in Patients with Active or Inactive Pulmonary Tuberculosis.Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents.Antiplatelet agents in hemodialysis.Antiplatelet Therapy and Spontaneous Retroperitoneal Hematoma: A Case Report and Literature Review.Iatrogenic bleeding during flexible bronchoscopy: risk factors, prophylactic measures and management.Manipulating integrin signaling for anti-thrombotic benefits.Uncertain Associations of Major Bleeding and Concurrent Use of Antiplatelet Agents and Chinese Medications: A Nested Case-Crossover Study.Total burden of intraplaque hemorrhage in coronary arteries relates to the use of coumarin-type anticoagulants but not platelet aggregation inhibitors.Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs.P2Y12 Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease.S3 guidelines for the management of anticoagulation in cutaneous surgery.A 24-year-old woman with heavy menstrual bleeding.

P2860

Q26749231-BA71AEB9-85F9-454B-A193-23444A79E930 Q28087427-222EF38B-6596-43FE-8867-1CC52430ADB3 Q28184366-36ECBB51-43B2-48B0-A3EB-43C24B372E74 Q28187602-B5441FC2-69FD-4CB9-A9A0-E235BAD065DF Q28193389-4482730A-20B1-464A-AF84-7AA720B23FAE Q28194069-A1A9F163-C505-4836-B54B-597D6C812090 Q28200403-1033FD7F-FA4C-4E1B-946D-091E832C3AED Q28218790-EF954C4A-64AB-4639-8FF6-2593588E0D02 Q30557151-50E6A41B-8C3C-4C38-B3F3-FB2A8C38E344 Q33846765-FAAE8B24-65F9-4C2A-9A9A-C6F1891D4FAD Q34092629-DE1501AF-3C89-483D-9F52-4FF0E59892DD Q34254787-5144054C-F95D-4857-989A-A3D123F0D7AC Q34775072-DCCFB5BD-5F49-4054-A907-83D9FD6F4D5E Q34775088-EF385990-7AF4-486A-AFD2-27767D9276FD Q35112024-DDD4C3AA-0B9D-41C8-A7E3-61784E6F0D28 Q35527043-24189D3F-73C7-41F6-800B-1CC881DF32E5 Q35551111-DB2DB009-9207-4DF2-9530-B9E1878DCFD1 Q36381490-7C7EC9F5-0805-465C-A2E6-C8781EC257A7 Q36440860-F85A1F00-081E-488F-A9C0-1FEC5E8F3999 Q37217894-DC8B4371-8EBD-4379-82A0-857E40836D2C Q37484189-954C4C20-5972-4366-AC7C-4AA05A0CA78E Q37969848-1980C9A5-5E04-446F-BD90-1962454D01BD Q38046968-9F0277F1-70B6-414B-91D9-DAD7F95ABAF4 Q38085222-A19815F7-F42A-4EF9-BED1-A72F8FE58C95 Q38415426-8EE40344-5504-460F-A121-1AFB99448C16 Q38578616-D9FAB00C-540B-4A53-87F7-E5105B393BE4 Q39032565-AE2CC116-A3B0-48AB-9731-30044733A597 Q39101773-DE2DD36C-0FF2-48BB-9D15-1D81A5CE6DF1 Q39401582-1E11FD39-882B-4E18-9F38-09AAA6821CC5 Q41282595-1E47FB55-8FE3-472B-A931-D6B0FEA31962 Q41430977-82EA58C4-4E80-4BA0-BB73-4E8BAD55100F Q44449780-8689CE48-75A3-42D4-A12B-C8EF6570A4D6 Q44461490-D70BE2DF-6F07-44BA-9072-52EBF27D46E8 Q47140310-C90BF5AB-A235-4285-9E87-0B074367DD8D Q52868326-75B6F786-8F82-449B-98F1-2D3662473F65 Q55288281-6EE0C371-847D-4B06-95DB-2C53E9154CD7

P2860

Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials

http://www.wikidata.org/entity/Q28166614

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Risk of bleeding complications ...... 0 randomized controlled trials

@ast

Risk of bleeding complications ...... 0 randomized controlled trials

@en

Risk of bleeding complications ...... 0 randomized controlled trials

@nl

type

label

Risk of bleeding complications ...... 0 randomized controlled trials

@ast

Risk of bleeding complications ...... 0 randomized controlled trials

@en

Risk of bleeding complications ...... 0 randomized controlled trials

@nl

prefLabel

Risk of bleeding complications ...... 0 randomized controlled trials

@ast

Risk of bleeding complications ...... 0 randomized controlled trials

@en

Risk of bleeding complications ...... 0 randomized controlled trials

@nl

P1433

Q28166614-996B9641-922B-46B2-A73B-E5D461C7C4FE

P1476

Q28166614-B2353AF9-C9A1-4582-BD7F-253A7FB83A94

P2093

Q28166614-6BC3C15F-9396-4F9D-BC6A-5471349C8CBC

Q28166614-9DCF3304-C6C4-4A73-B510-B6CF9B62731B

Q28166614-C463EEBD-42A5-4B03-A245-7DAADFA6C84D

Q28166614-DA5243FC-8A89-4DD9-B91F-DADC9715C801

P2860

Q28166614-3B345F92-488C-40D0-BDEE-D4960F1E8525

Q28166614-4E9644E3-3547-44E2-BB91-29BD10A1A42F

Q28166614-5D829037-E8A8-4313-838C-29600AED765E

Q28166614-6F338700-ABE3-4044-A701-FA971D92AFE3

Q28166614-91F72419-3E43-4567-9CE5-44F4E5CEC59F

Q28166614-9A379509-BA12-4F37-BDAC-6029C3BB391D

Q28166614-B01AF94F-702F-4E3B-871E-5D098E2C368E

Q28166614-C1BCE425-3CF4-4742-88C9-F2F58220CB43

P304

Q28166614-462BFF0C-E58F-41D2-A460-C1D65E7361C5

P31

Q28166614-0B44A6D1-C660-4402-B5A3-1D4BB39CAA32

Q28166614-37AF61D5-45FC-4EA7-8B5B-6A55028A42A3

P356

Q28166614-3545628C-FCB2-4E06-B066-01F1B934BB63

P407

Q28166614-2690B5DD-1AD1-4BB7-A0E4-1FF0474EE14C

P433

Q28166614-356667E4-37E7-412F-A207-B7581315ADCE

P478

Q28166614-20B59C9B-B3F8-4246-9DD3-BBB099145A3F

P577

Q28166614-32219D3C-C1EC-4E92-A73C-DEE00652A425

P5875

Q28166614-83BFEB78-A2E6-427D-A087-A9013E8E117E

P698

Q28166614-A74523B4-1E52-4A05-B061-C2CDFCF31614

P921

Q28166614-5DF3E8D2-2F91-43F0-81A5-6EA8D9F30D72

Q28166614-6EC7876D-19A4-4476-8F92-77486CA666B6

P356

P1433

American Journal of Hematology

P1476

Risk of bleeding complications ...... 0 randomized controlled trials

@en

P2093

Alex I Malinin

http://www.w3.org/2001/XMLSchema#string

David C Sane

http://www.w3.org/2001/XMLSchema#string

Roswith M Eisert

http://www.w3.org/2001/XMLSchema#string

Victor L Serebruany

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes

Final report on the aspirin component of the ongoing Physicians' Health Study

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

Mitral valve rupture following percutaneous mitral commissurotomy: existence of predictive factors.

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

P304

40-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.10451

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8941440

http://www.w3.org/2001/XMLSchema#string

P698

14695631

http://www.w3.org/2001/XMLSchema#string

P921